Q32 Bio (QTTB) Current Deferred Revenue (2017 - 2023)

Q32 Bio's Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $354000.0 for Q1 2023.

• On a quarterly basis, Current Deferred Revenue fell 88.97% year-over-year to $354000.0 in Q1 2023; TTM through Mar 2023 was $354000.0, a 88.97% decrease from a year earlier, with the FY2022 full-year figure at $1.2 million, down 63.97% from the prior year.
• Current Deferred Revenue retreated to $354000.0 in Q1 2023 per QTTB's latest filing, from $1.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $5.6 million in Q4 2020 and bottomed at $354000.0 in Q1 2023.
• The 5-year median for Current Deferred Revenue is $1.2 million (2021), against an average of $2.1 million.
• Across the five-year window, Current Deferred Revenue soared 596.17% in 2020 and tumbled 88.97% in 2023, its largest moves.
• Year by year, Current Deferred Revenue stood at $809000.0 in 2019, then surged by 596.17% to $5.6 million in 2020, then sank by 43.04% to $3.2 million in 2021, then slumped by 63.97% to $1.2 million in 2022, then tumbled by 69.38% to $354000.0 in 2023.
• Per Business Quant, the three latest QTTB Current Deferred Revenue figures stand at $354000.0 (Q1 2023), $1.2 million (Q4 2022), and $2.0 million (Q3 2022).